LLY

1,034.66

-2.08%↓

JNJ

205.59

+1.04%↑

ABBV

229.43

+2.73%↑

UNH

336.82

+3.99%↑

AZN

90.8

+0.33%↑

LLY

1,034.66

-2.08%↓

JNJ

205.59

+1.04%↑

ABBV

229.43

+2.73%↑

UNH

336.82

+3.99%↑

AZN

90.8

+0.33%↑

LLY

1,034.66

-2.08%↓

JNJ

205.59

+1.04%↑

ABBV

229.43

+2.73%↑

UNH

336.82

+3.99%↑

AZN

90.8

+0.33%↑

LLY

1,034.66

-2.08%↓

JNJ

205.59

+1.04%↑

ABBV

229.43

+2.73%↑

UNH

336.82

+3.99%↑

AZN

90.8

+0.33%↑

LLY

1,034.66

-2.08%↓

JNJ

205.59

+1.04%↑

ABBV

229.43

+2.73%↑

UNH

336.82

+3.99%↑

AZN

90.8

+0.33%↑

Search

CareDx Inc

Abierto

SectorSanidad

18.11 3.25

Resumen

Variación precio

24h

Actual

Mínimo

17.35

Máximo

18.15

Métricas clave

By Trading Economics

Ingresos

10M

1.7M

Ventas

13M

100M

P/B

Media del Sector

14.031

79.874

Margen de beneficios

1.674

Empleados

644

EBITDA

11M

6.8M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+39.7% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

170M

956M

Apertura anterior

14.86

Cierre anterior

18.11

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

162 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

CareDx Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 dic 2025, 17:29 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

Laurentian Bank Shares Hit Two-Year High on Plans for Break-Up, Takeover

2 dic 2025, 16:21 UTC

Ganancias

Scotiabank Aiming for Earnings Growth After Capital Markets Buoy Results in Latest Quarter -- Update

2 dic 2025, 16:18 UTC

Ganancias

Correction to Scotiabank Quarterly Earnings Buoyed Article

2 dic 2025, 23:53 UTC

Charlas de Mercado

Nikkei May Rise After Gains on Wall Street -- Market Talk

2 dic 2025, 22:48 UTC

Ganancias

Marvell's Stock Soars On Data Center Forecast -- Barrons.com

2 dic 2025, 22:12 UTC

Charlas de Mercado

Australian 3Q GDP To Show Modest Recovery In Play -- Market Talk

2 dic 2025, 22:03 UTC

Charlas de Mercado

Minerals 260's Resource Upgrade Looks Impressive -- Market Talk

2 dic 2025, 22:00 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 dic 2025, 22:00 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 dic 2025, 22:00 UTC

Charlas de Mercado

Fletcher Building Loses Bull Due to Tame Housing-Market Recovery -- Market Talk

2 dic 2025, 21:56 UTC

Ganancias

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dic 2025, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

2 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

2 dic 2025, 21:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

2 dic 2025, 21:44 UTC

Ganancias

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dic 2025, 21:38 UTC

Charlas de Mercado

Sky Network TV Has Path to Grow Dividend by 33% -- Market Talk

2 dic 2025, 21:19 UTC

Ganancias

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dic 2025, 20:06 UTC

Charlas de Mercado

Oil Futures Fall Amid Russia-Ukraine Peace Talks -- Market Talk

2 dic 2025, 19:55 UTC

Charlas de Mercado

Natural Gas Futures Fall Amid Uncertain Weather Forecasts -- Market Talk

2 dic 2025, 19:53 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

2 dic 2025, 19:53 UTC

Charlas de Mercado
Ganancias

Scotiabank ROE Target Viewed as Possibly Conservative -- Market Talk

2 dic 2025, 19:24 UTC

Charlas de Mercado

Analysts Project Uptick in U.S. Ethanol Stocks -- Market Talk

2 dic 2025, 19:06 UTC

Charlas de Mercado

Precious Metals Step Back After Silver Sets Record -- Market Talk

2 dic 2025, 18:27 UTC

Adquisiciones, fusiones, absorciones

Kraken to Acquire Backed Finance AG

2 dic 2025, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

2 dic 2025, 17:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

2 dic 2025, 15:17 UTC

Charlas de Mercado

Natural Gas Extends Gains Amid Cold Weather -- Market Talk

2 dic 2025, 14:47 UTC

Charlas de Mercado

BOE Likely to Cut Rates Further, Weakening Sterling -- Market Talk

2 dic 2025, 14:38 UTC

Charlas de Mercado

Silver Steps Back From Record Levels -- Market Talk

2 dic 2025, 14:31 UTC

Charlas de Mercado
Ganancias

Scotiabank Strong Quarter Driven By Capital Markets Growth -- Market Talk

Comparación entre iguales

Cambio de precio

CareDx Inc previsión

Precio Objetivo

By TipRanks

39.7% repunte

Estimación a 12 Meses

Media 24 USD  39.7%

Máximo 26 USD

Mínimo 22 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CareDx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

2

Comprar

2

Mantener

0

Vender

Puntuación técnica

By Trading Central

14.77 / 18.49Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

162 / 374 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat